J.P. Morgan MicroPort MedBot (2252.HK): Toumai Reaches 300+ Orders; Tracking Above-Street FY26 Sales Estimates with Upside from Operating Leverage, Telesurgery, and AI
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
J.P. Morgan highlights that MicroPort MedBot (2252.HK) has successfully secured over 300 orders for its flagship Toumai surgical robotic system, keeping the company firmly on track to meet the firm's above-consensus fiscal year 2026 sales projections. J.P. Morgan maintains an Overweight investment recommendation, citing additional upside potential driven by operating leverage, telesurgery capabilities, and future artificial intelligence integration. The firm projects fiscal 2026 Toumai deliveries of approximately 100 units, translating to an estimated 500 million yuan in revenue, which notably exceeds the broader market consensus of 80 units. As production volumes scale, the resulting fixed-cost dilution should unlock meaningful operating leverage and progressively improve gross margins. Furthermore, the system's recently approved telesurgery functionality provides a distinct competitive advantage, effectively expanding the addressable market into grassroots and regional hospitals. The company is also advancing its AI-assisted surgical platform, with commercialization anticipated within the next two to three years. Financial flexibility remains adequate, supported by roughly 1.5 billion yuan in cash equivalents at the end of fiscal 2025. Toumai currently leads the domestic laparoscopic robotics segment, bolstered by favorable national procurement policies accelerating domestic substitution. Early international expansion into Southeast Asia is also generating incremental revenue. Key risks include slower-than-expected penetration rates and escalating competitive pressures. The target price was not explicitly disclosed.
Key exhibits
Exhibit 1
Exhibit 2
